Xeris Biopharma Holdings, Inc. (XERS)

1.8900 +0.0300 (+1.61%) 收市：04:00PM EDT

Xeris Biopharma Holdings, Inc.

180 North LaSalle Street
Suite 1600
Chicago, IL 60601
United States
844 445 5704
https://www.xerispharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 377

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Paul R. Edick	Chairman & CEO	1.21M	無	1956
Mr. John P. Shannon	President & COO	918.15k	無	1962
Mr. Steven M. Pieper	Chief Financial Officer	681.14k	無	1978
Ms. Beth P. Hecht J.D.	Chief Legal Officer & Corporate Secretary	695.44k	無	1964
Dr. Kenneth E. Johnson Pharm. D., Pharm.D.	Senior VP of Global Development & Medical Affairs	596.97k	無	1963
Ms. Allison Wey	Senior Vice President of Investor Relations & Corporate Communications	無	無	無
Mr. Kevin McCulloch	Chief Commercial Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

公司管治

截至 2024年5月1日 止，Xeris Biopharma Holdings, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：9；董事會：9；股東權利：8；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。